Loading clinical trials...
Loading clinical trials...
A Randomized, Controlled, Multi-center, Safety and Efficacy Study of FCR001 Cell-based Therapy Relative to a Tacrolimus and Mycophenolate-based Regimen in de Novo Living Donor Renal Transplant Recipients, and Safety in FCR001 Donors
Conditions
Interventions
FCR001
Locations
18
United States
Mayo Clinic
Phoenix, Arizona, United States
Scripps Clinic
La Jolla, California, United States
University of California, San Francisco
San Francisco, California, United States
Georgetown University Hospital
Washington D.C., District of Columbia, United States
Mayo Clinic
Jacksonville, Florida, United States
Northwestern Memorial Hospital
Chicago, Illinois, United States
Start Date
October 25, 2019
Primary Completion Date
February 16, 2023
Completion Date
February 16, 2023
Last Updated
March 3, 2023
Lead Sponsor
Talaris Therapeutics Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions